Controlling HIV infection continues to be a major challenge in both underdeveloped and developed nations. Although the drug cocktails used in highly active antiretroviral therapy (HAART) have markedly changed the profile of progression to AIDS in HIV-infected individuals, they are not without significant problems and drawbacks. Pharmacokinetic differences between individuals result in many drugrelated toxicities, leading to problems of nonadherence, although the increase in side effects is due in part to the improved lifespan brought by the very success of antiretroviral therapies. There is a need for personalized dosing regimens and combinations and for continued therapeutic monitoring of the drugs themselves. Drug failures for those on HAART continue to occur as a consequence of viral resistance and other complications arising from a lifelong regimen of chemotherapy. In addition, treatment guidelines traditionally have not recommended initiating therapy in the early stages of infection, despite the risks associated with loss of immunological function, increased likelihood of transmission and development of a larger pool of viral subspecies that serve as a reservoir for potential resistance. However, there has been a recent shift toward starting retroviral therapy when the CD4 count is in the range of 300 × 10 6 to 350 × 10 6 /liter (Office of AIDS Research Advisory Council guidelines, http://AIDSinfo.nih.gov) 1,2 .
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The importance of developing new antiretroviral drugs cannot be overstated. However, that HAART is lifelong and may be associated with cumulative toxicities underscores the need for new approaches. Given the increasing knowledge of mechanisms that allow control of HIV infection 2 , several investigators are focusing their attention on gene therapy, either as a stand-alone approach or as an adjuvant to pharmacological regimens. Several million HIV-infected individuals live in settings where there is sufficient infrastructure to support such an approach with current technology. Gene-based approaches present conundrums and trade-offs analogous to those of conventional drugs. One consideration is the issue of viral versus cellular targets. RNA antivirals can be designed with high specificity, and HIV-1 products are the preferred target (Fig. 1) . However, viral escape is a major problem that will confound even gene therapy approaches. Cellular targets are far less prone to mutational escape, but the side effects of downregulating cellular targets for the long term are unknown. This article reviews some of the genetic approaches that have been used in gene therapy clinical trials for HIV-1 treatment as well as approaches that are about to be tested. We also discuss the virtues and problems associated with T-cell therapies versus hematopoietic stem (HS) cell therapies for the treatment of HIV-1 infection in the era of HAART. The review is not meant to be exhaustive but should provide an overview of the possibilities for treating HIV-1 infection using gene therapy either as a stand-alone approach or in conjunction with HAART.
Targeting HIV genes and their products
Over the past 15 years several different anti-HIV-1 gene therapy approaches have been tested in hematopoietic cells. These approaches can be classified into two categories ( Fig. 2) : (i) RNA-based agents (including antisense, ribozymes, aptamers and RNA interference (RNAi)); and (ii) protein-based agents (including dominant-negative proteins, intrabodies, intrakines, fusion inhibitors and zinc-finger nucleases).
RNA-based inhibitory agents.
Ribozymes are antisense RNAs that enzymatically cleave targeted mRNAs. Since the first demonstration that ribozymes can inhibit HIV replication 3 , hundreds of publications have demonstrated related ribozyme-based strategies for the treatment of HIV infection. Three separate clinical trials have used ribozymes targeting HIV genes, including tat, rev and the viral U5 region. The ribozymes were expressed either from the retroviral long terminal repeats (LTRs) as long, capped, polyadenylated transcripts from the retroviral LTR promoter [4] [5] [6] or as a discrete, chimeric polymerase III (Pol III) tRNA-ribozyme transcript 7 . Two of the trials involved retroviral vector delivery of the ribozyme genes into autologous hematopoietic progenitor cells isolated from HIV-1-infected individuals. After retroviral transduction the cells were reinfused into the patients either without bone marrow conditioning, or in one case, with bone marrow conditioning to treat AIDS-related lymphomas [4] [5] [6] . The third trial used autologous peripheral blood mononuclear cells isolated from HIV-infected individuals that were transduced with a retroviral vector expressing a single hairpintype ribozyme 7 . Although these trials have not shown significant anti-HIV efficacy, they demonstrated that it is safe to mobilize stem cells or to collect peripheral blood mononuclear cells from persons with HIV, genetically modify the cells with retroviral-ribozyme vectors and reinfuse them into patients. The level of marking achieved in these studies was very low, however, so they may not support the safety of current HS cell gene transfer protocols, where much higher levels of gene transfer are likely to be observed.
Short and long antisense RNA transgenes that simply pair with HIV transcripts to form nonfunctional duplexes have also proven to be effective in blocking HIV replication in hematopoietic cells. The first demonstration of this principle came from studies using adeno-associated virus to deliver a short anti-U5-region antisense RNA 8 . More recently, a clinical trial using an HIV LTR-expressed anti-env antisense has been reported 9 . Although the actual mechanism by which these antisense transcripts inhibit HIV replication is not clear, it may involve triggering extensive adenosine deamination of the HIV-antisense duplex, resulting in nuclear retention of transcripts or the generation of multiple viral-disabling mutations 10 .
Another group of RNA molecules, RNA aptamers, have been evolved in vitro to bind targeted ligands with high affinity [11] [12] [13] . Although aptamers against HIV show promise, thus far there have been no clinical trials using anti-HIV aptamers. One potential problem is that aptamers selected in vitro may not form the required tertiary structure in cells to effectively bind target proteins. On the other hand, expressed RNA decoys based on HIV TAR (trans-activating response region) and RRE (Rev responsive element) are amenable to gene therapy, and one of us (D.B.K.) has tested in the clinic an expressed RRE decoy that binds and sequesters Rev 14 . RNAi is a regulatory mechanism of most eukaryotic cells that uses small double-stranded RNA molecules as triggers to direct homology-dependent control of gene activity 15 . Known as small interfering RNAs (siRNAs), these ~21-to 22-base pair (bp) double-stranded RNA molecules have characteristic two-nucleotide 3′ overhangs that allow them to be recognized by the host RNAi enzymatic machinery, leading to homology-dependent degradation of the target mRNA (Fig. 2) . RNAi triggers can be produced by expressing short hairpin (shRNA) precursors that partly resemble endogenous microRNA precursors, allowing them to be exported to the cytoplasm and processed by the RNAi machinery. Expressing short hairpin precursors encoding siRNAs targeting viral or cellular sequences can be readily accomplished from the backbone of viral vectors used in gene therapy.
HIV-1 was one of the first infectious agents targeted by RNAi as a result of the virus' well-understood life cycle and pattern of gene expression. Virtually all the HIV-encoded RNAs-including tat, rev, gag, pol, nef, vif, env, vpr and the LTR-are susceptible to RNAi downregulation in cell lines [16] [17] [18] [19] [20] . A substantial challenge for clinical applications of RNAi triggers is the high viral mutation rate of HIV, which generates mutants that escape being targeted [21] [22] [23] [24] . One approach to avoid this problem is to target cellular transcripts that encode functions required for HIV-1 entry and replication. To this end, cellular cofactors such as nuclear factor kappa B (NF-κB), the HIV receptor CD4 and the co-receptors CCR5 (C-C motif receptor 5) and CXCR4 (C-X-C motif receptor 4) have all been downregulated, thereby blocking viral replication or entry 18, 19, [25] [26] [27] [28] .
Enthusiasm for targeting CD4 is diminished by genetic studies indicating that CD4 disruption causes substantial immunodeficiency. In contrast, the macrophage-tropic CCR5 co-receptor holds particular promise as a target. Disruption of CCR5 is compatible with immune function, in that individuals homozygous for the 32-bp deletion mutant of CCR5 receptor (delta32-CCR5) are more resistant to R5 strains of HIV than individuals who express the wild-type receptor [29] [30] [31] . Several major pharmaceutical companies have initiated programs to develop small molecules or antibodies to block the binding of HIV to CCR5, and one such drug, maraviroc (Selzentry), developed by Pfizer, has been recently approved. CXCR4 is essential for homing of HS cells to bone marrow and subsequent T-cell differentiation [32] [33] [34] , and targeting this receptor may not therefore be a viable approach. At the same time, targeting the CCR5 co-receptor alone may be insufficient, in that HIV-1 switches to CXCR4 tropism during the course of AIDS, sometimes creating a more virulent infection 35 . Such considerations suggest that downregulation of both viral and host targets should be considered in any RNAi strategy against HIV. Targeting of other host genes involved in the viral life cycle (for example, the LEDGF/p75 protein, which facilitates HIV-1 integration) may also prove beneficial. Katie Ris-Vicari
As described above, siRNAs can be produced from shRNA precursors ( Fig. 2) expressed from retroviral or lentiviral vector backbones by transcription from either Pol III or Pol II promoters. Because the transcription units are short in both cases, shRNAs can readily be multiplexed in various combinations. Using multiple shRNAs to target separate conserved sites in HIV-akin to the HAART approachshould prevent cross-resistance among different RNAi effectors or among RNAi effectors and conventional pharmaceuticals. Multiple RNAi effectors would thus have the advantage of limiting escape and targeting a range of sequences as is found in different viral genotypes or quasi species 36, 37 . Viruses that escape the antiviral effects of RNAi can be reinhibited by targeting different sequences. Thus, a multiple inhibitory approach should aim to target distinct genomic regions of HIV-1 or, alternatively, target host-derived factors that contribute to viral replication.
A potential drawback of using multiple shRNAs is that expressed hairpins and the siRNAs processed from them can compete with endogenous microRNAs for nuclear-to-cytoplasmic export and incorporation into the RNA silencing machinery. The expression levels of shRNAs can be a critical determinant of whether they are toxic, so caution is necessary in using expressed shRNAs for gene therapy 28, 38 . The toxicity of an shRNA targeting CCR5 in primary blood mononuclear cells has been shown to depend on its absolute expression level and is alleviated by damping expression 28 .
Rather than relying solely upon RNAi for anti-HIV therapy, a potent combinatorial approach is to mix an shRNA with other antiviral genes. For example, one of our groups (J.J.R.) has co-expressed from a single vector backbone an anti-tat/rev shRNA, a nucleolar localizing TAR decoy and an anti-CCR5 ribozyme 39 . This triple combination vector has recently been approved by the US Food and Drug Administration (FDA; Rockville, MD) for use in a clinical trial of autologous peripheral blood stem cell transplantation in AIDS/lymphoma patients at the City of Hope Medical Center in Duarte, California and is a combined effort between City of Hope and Benitec, Inc. The first patients are currently undergoing eligibility screening for entry into this trial. A somewhat different combination used an shRNA with a dominant-negative Rev M10 protein in a co-expression system; this may represent a future direction for Tat-regulated expression of antiviral transgenes 40 .
Protein-based inhibitors. Similar to the RNA-based inhibitors of HIV, proteins can be directed to inhibit either cellular or viral targets. The majority of the protein inhibitors have been expressed from the viral vector LTRs, but in several instances they were produced from strong constitutive promoters inserted within the bodies of the viral vectors. The first protein used in an HIV gene therapy trial is a mutant form of the HIV Rev protein called M10 (ref. 41 ). Rev M10 is believed to work by blocking the export of singly spliced and unspliced HIV RNA from the nucleus to the cytoplasm, thereby preventing packaging and subsequent transmission. This mutant protein is one of the most potent inhibitors of HIV replication. Intracellular antibodies and intrakines have also proven to be very potent inhibitors of HIV replication [42] [43] [44] [45] [46] . These proteins work by binding to viral or cellular target proteins, most often resulting in targeting of the proteins to the proteasome for degradation. Of all these approaches, thus far only the M10 dominant-negative protein has been tested in human clinical trials 41 .
A new entrant in the pool of protein-based agents is fusion inhibitors, which bind to HIV gp41 at the cell surface and block viral entry 47, 48 . As with the other protein-based inhibitors, these entry-blocking proteins can be expressed constitutively from the backbone of retroviral or lentiviral vectors, making them suitable for use in gene therapy.
A different protein-based approach uses zinc-finger nuclease (ZFN) fusion proteins 49 . ZFN proteins can be engineered to bind with exquisite selectivity to specific sequence motifs in the genome, and the associated nuclease cleaves the targeted DNA. When these double-stranded breaks are repaired, high-frequency deletions and insertions are introduced at the site of cleavage. The CCR5 gene is a target for ex vivo gene therapy of HS cells. Disruption of the coding sequence of this gene will generate nonfunctional CCR5 mutants, rendering the cells resistant to CCR5-tropic HIV. The challenge with this approach is to transiently introduce the ZFN protein or a genetic transcription unit into primary hematopoietic cells (stable expression of the ZFN may cause genotoxicity) 50 . The goal is to have a single hit of mutagenesis and eliminate the nuclease from the cells after that hit. The efficiency of ZFN-mediated gene modification must be high to achieve bi-allelic CCR5 gene knockout. Despite these challenges, this is a particularly exciting approach in that the ex vivo-modified cells should have a selective growth advantage in HIV-infected individuals. Furthermore, the recent approval of CCR5 inhibitor maraviroc for advanced HIV infection increases enthusiasm for strategies that target this co-receptor. That said, the emergence of dual-tropic or CXCR4-tropic virus would abrogate this advantage. In addition, potential genotoxicities of ZFNs, from chromosomal breakage, such as translocations, or effects of 'off-target' DNA cleavage, must also be determined.
T-cell gene therapy
As the role of T cells in adaptive cell-mediated immune responses against viral agents becomes better understood, opportunities are increasing for their co-option for anti-HIV treatments.
Advances in T-cell biology.
Advances in the understanding of T-cell biology coupled with the advances in genetic engineering described above have led to several new adoptive transfer strategies that are now poised for translation into clinical trials. Over the past decade, significant advances have been made in the manipulation and growth of T cells ex vivo. In particular, the discovery that the anergy induced by stimulation of T cells with CD3 alone could be overcome through costimulation of the CD3 and CD28 receptors permitted large-scale amplification of T cells [51] [52] [53] . Furthermore, CD28 costimulation induces a state of resistance ad interim to HIV infection by CCR5-tropic virus in CD4 + cells 53 . The feasibility of T-cell processing to produce sufficient doses of cellular product from HIV-infected individuals has been demonstrated. Early trials raised safety concerns about administration of CD4 + cells to those infected with HIV 54 ; however, the viral load of HIV-infected individuals is not increased by adoptively transferred CD4 + T cells produced using present processing, expansion and infusion technologies 55 . Although the T-cell-based HIV gene therapy trials thus far have reported no or modest effects on viral load, they have established an encouraging body of data supporting safety, a selective advantage of gene-modified HIV-resistant T cells in vivo and the ability of gene-modified CD4 + T cells to persist long term. T-cell therapy may also prove to be a fertile testing and validation ground for subsequent stem cell-based clinical trials, which take longer to reach endpoints.
T-cell subsets. CD4 + T cells exist in several distinct stages of differentiation. Naive CD4 + T cells undergo unique developmental programs after antigen activation, generating effector memory T cells (T EM ) and long-lived central memory T cells (T CM ). The T CM cells, being the least differentiated of the antigen-stimulated T cells, retain the developmental options of naive T cells, including their capacity for marked clonal expansion and self-renewal 56 . In adoptive transfer experiments, T CM cells show superior therapeutic effects compared with T EM cells on a per-cell basis 57 . Thus, the long-term survival of subsets of T cells has increased enthusiasm for T-cell-based gene therapy trials. Genetically modified T cells persist for more than a decade in children with adenosine deaminase deficiency 58 .
Adoptive immunotherapy strategies. AIDS is a disorder of the immune system that is caused by collapse of immunity driven primarily by depletion of CD4 + T cells. Therefore, prevention of AIDS onset by protection of the CD4 + T-cell compartment by genetic modification is an attractive hypothesis. Possible in vivo mechanisms of action of gene-modified T cells that may lead to clinical benefit include: (i) selective outgrowth of HIV-resistant cells to a tipping point where overall HIV replication is thwarted 59, 60 ; (ii) generation of an expanding HIV-resistant T-cell population through spread of conditionally replicating HIV vectors 61 ; (iii) protection and/or boosting of critical HIV-specific immunity by HIV-resistant helper cells. A combination of these approaches may be required for success.
Preventing viral entry.
Modeling studies suggest that blocking of an early step in the HIV life cycle will be important to confer a selective advantage to vector-modified cells in vivo and hence to allow outgrowth of HIV-resistant cells in the patient 60 . In 2003, the new antiretroviral drug enfuvirtide (Fuzeon; Roche), commonly known as T20, was adopted into clinical practice 62 . T20 blocks HIV entry by inhibiting the conformational changes needed for fusion of the viral envelope with the cellular membrane. In a genetic approach, von Laer and colleagues 47 have developed a retroviral vector (M87o) that encodes the membrane-anchored antiviral peptide C46, which contains T20 sequences and is derived from the second heptad repeat of the HIV-1 envelope glycoprotein gp41. A pilot clinical trial was carried out by van Lunzen et al. 63 in 10 patients with late-stage HIV/AIDS and HAART failure, who received an infusion of CD4 + T cells transduced with the retroviral M87o vector. The approach was shown to be safe, although viral loads were not affected, despite a significant rise in CD4 + T-cell counts. Gene marking was detected throughout the 1-year followup. The M87o payload has also been inserted in a lentiviral vector and was effective in preclinical studies 48 . Single-chain antibodies that bind gp120 were tested in CD4 + cells and found effective in preclinical studies 64 . Although resistance has not yet been documented in the gene therapy setting, the emergence of resistance after T20 treatment suggests that it may be important to use anti-HIV surface peptides in combination with other surface inhibitors or other modalities to interfere with the virus' replication cycle 65 .
The CCR5 and CXCR4 co-receptors have been targeted in T cells using ribozymes, RNAi, intrakines, single-chain antibodies (intrabodies) and ZFNs 66, 67 . As a variation on this, trans-dominant mutant
Box 1 Mobilizing vectors, defective interference and conditional replication: friend or foe?
Most viral vectors are engineered to be nonreplicating. However, in some circumstances it may be advantageous for vectors to mobilize and spread their anti-HIV sequences throughout the T-cell population and other HIV reservoirs in the body. Naturally occurring and engineered defective interfering viruses have been described that consist of mutated or deleted pathogenic viruses that replicate and compete for packaging into virions at the expense of infectious helper virus 130, 131 . Conditionally replicating HIV vectors contain none of the trans elements necessary for viral packaging and instead carry an antiviral gene that inhibits any of numerous wild-type HIV-1 functions 132 . At the cellular level, conditional replication has the potential to convert viral-producing cells into latently infected cells by competing for factors that are required for HIV replication. If a cell carrying an integrated copy of a conditionally replicating HIV vector becomes infected with wild-type virus, the antiviral vector payload acts to limit the production of HIV. A model describing the potential for conditionally replicating anti-HIV vectors to overcome wildtype infection in vivo has been described 59 . Conditional replication that was self-limiting has occurred during a T-cell gene therapy trial 9 ; however, the long-term safety of this approach remains to be demonstrated.
variants of CCR5 also interfere with HIV infection of CD4 + T cells 68 . Lentiviral vectors expressing a single-chain antibody against CCR5 in primary CD4 + T cells disrupt CCR5 cell surface expression and provide protection from R5-tropic viral isolates 69 . Single-chain antibodies targeted to CXCR4 and cyclin T1 inhibit the replication of various HIV strains 70, 71 . Further testing is required, however, to show that targeting such cellular factors in primary lymphoid cells will not result in immunodeficiency or toxicity.
Expression of rhesus tripartite motif 5α (TRIM5α) protein, which binds to the HIV capsid and interferes with the uncoating process, strongly protects human cells from productive HIV-1 infection 72 . The human version of TRIM5α is not efficient at blocking HIV, presumably because the capsid protein has evolved to reduce the interaction 73 . Changing one residue in human TRM5α confers substantial resistance to infection by HIV-1 in human cells, mimicking the rhesus phenotype 74 . Thus, gene therapy using this gene may not be immunogenic, because only minor modifications to human TRIM5α are sufficient to augment innate HIV-1 resistance by increasing affinity for the HIV capsid, which could result in efficient destruction of the viral particle.
Early genetic antivirals in T cells. The first proof that genetic antivirals can protect cells from HIV in vivo was in a clinical competitive repopulation experiment: CD4 + T lymphocytes were genetically modified to express either the trans-dominant-negative protein Rev-M10 or a marking vector with no antiviral payload, and a mixture of both was infused 41, 75 . Autologous CD4 + T cells were modified with gold microparticles or by a murine leukemia virus (MLV) vector expressing the dominant-negative protein. Analysis of engraftment showed that the transduced cells containing the antiviral gene but not the controltransduced cells had a selective advantage in individuals chronically infected with HIV. Cells expressing Rev-M10 were detectable for an average of 6 months compared with 3 weeks for control cells.
More recently, Morgan et al. 76 have reported long-term engraftment of T cells engineered to express an antisense TAR element or Rev M10. Robust antiviral effects were documented, particularly in patients with high viral loads. Furthermore, Macpherson et al. 77 have reported persistent engraftment of T cells for longer than 4 years after treatment of syngeneic CD4 + T cells with an MLV vector expressing an anti-tat ribozyme. This study was similar to that of reference 75 in that cells were transduced either with an empty vector or a vector expressing an anti-HIV-1 payload. But in contrast to references 75 and 76, no selective advantage of the HIV-resistant CD4 + cells was observed. However, a companion study testing this vector in CD34 + cells did observe a selective survival advantage for CD4 + cells derived from CD34 + cells 78 .
Lentiviral vectors in the clinic.
Numerous antisense targets have been tested in preclinical studies targeting both coding and noncoding regions of the HIV-1 genome, and many effectively inhibit HIV-1 replication [79] [80] [81] .The first clinical trial to use lentiviral vectors was recently reported 9 . The vector expressed a long antisense against the HIV-1 envelope gene in autologous CD4 + T cells. Vector delivery was efficient, with an average of one to two vector copies per cell, and engraftment and persistence were prolonged, with ongoing detection of gene-modified T cells for more than 1 year in two of the subjects. The magnitude of engraftment ranged from ~0.1% to 4% of CD4 + cells 90 d after infusion of genetically modified CD4 + cells. Transient vector mobilization was observed, most likely because cis-acting sequences remained intact (Box 1). Analyses of vector integration sites in blood cells revealed a preference for gene-rich regions typical of lentivirus 82 . Follow-up over 3 years has not detected any adverse clinical effects. Notably, there has been no evidence of insertional mutagenesis 83, 84 . A second phase 1/2 trial is under way to evaluate the therapy using structured treatment interruption, and a follow-up phase 2 repeat-dosing exploratory trial is in progress. Many other groups have developed lentiviral vectors with various payloads that confer antiviral effects in T cells. The vectors designed by the group of J.R.R. are described above 39, 85 . Another group designed an HIV-1 LTR-specific translational inhibitor that seems promising in preclinical studies 86 .
Targeting CD8 + T cells. Substantial data exist to indicate that CD8 + T cells can affect the outcome and viral load in HIV-1 infection. Naturally occurring gag-specific cytotoxic T-lymphocyte (CTL) responses are inversely associated with viremia 87 . Adoptive therapy with natural CTL clones for cytomegalovirus and Epstein-Barr virus infection is effective in immunosuppressed individuals 88, 89 . In contrast, adoptive CTL therapy for HIV/AIDS, though demonstrating safety and promising engraftment and trafficking of cells to sites of viral replication, has not been clinically effective 90 . Mathematical modeling suggests that adoptive transfer of CTLs should augment HIV-1 immunity and control viral replication, but only when the replicative capacity of the genetically modified CTLs is preserved and functional CD4 + T cells are present 59, 91 . Thus, an attractive strategy is the use of genetically enhanced CTLs to facilitate immune-mediated control of viral replication. Ultimately, a two-pronged approach of CD4 + T-cell protection and CTL augmentation therapy might be optimal.
T-body approaches. Studies initiated in the early 1990s examined the potential of engineering HIV-specific CTLs using the CD4 extracellular domain or a gp41-specific antibody coupled to the ζ signaling chain of the CD3 T-cell receptor (TCR) 92, 93 , generating antibodybased chimeric proteins expressed in T cells known as 'T bodies' . These preclinical studies showed that redirected CD8 + T cells respond by interleukin-2 secretion upon binding to HIV-1 and have robust CTL activity against HIV-1 in vitro equal to that of natural CTLs. The CD4-CD3ζ approach has since been translated to the clinic [94] [95] [96] . Analysis of rectal mucosal biopsy specimens and of peripheral T cells showed lymphoid tissue trafficking and stable engraftment of modified cells. In one study the CD4-CD3ζ transgene was detected in 1-3% of blood mononuclear cells at 8 weeks and at 0.1% frequency 1 year after infusion 95 . A randomized phase 2 study of the CD4-CD3ζ vector in 40 patients (20 treated and 20 control patients) confirmed that T-cell infusions resulted in elevated CD4 + T-cell counts and stable persistence of vector-modified cells 96 . This trial also showed modest antiviral effects (P < 0.07) on the viral reservoir in well-controlled patients and established the feasibility of multicenter phase 2 trials with genetically modified T cells. Together with another natural CD4 + T-cell adoptive transfer trial not discussed here 55 , these trials provide substantial data demonstrating the safety of multiple infusions of gene-modified autologous T cells in HIV-infected individuals.
Engineered TCRs. The failure of most patients to control HIV-1 replication is related to acquired CTL dysfunction and TCR repertoire contraction 97, 98 . In preclinical studies, Cooper and colleagues 99 isolated a human leukocyte antigen (HLA)-A3-restricted p17 gag-specific TCR from a donor infected with HIV-1. Using a retroviral vector they expressed this TCR in CD8 + T-cell clones and showed that the clones killed HIV-infected cells. Advances in vector design with TCRs now permit clinical testing of approaches to convert polyclonal T cells into redirected potent CTLs, a strategy that has shown promise in cancer patients 99 . In that trial, retroviral gene transfer of redirected TCRs for MART-1 in CD8 + CTLs was found to be safe in melanoma patients.
Improving the affinity of natural TCRs could be beneficial in HIV. This concept is supported by a recent study in which a T-cell line engineered to contain a high-affinity TCR (K d = 10 nM) responded to significantly lower peptide concentrations than cells expressing the parental TCR 100 . Several approaches are under investigation, such as improving the intrinsic avidity of the TCR or improving functional avidity by enhancing signal transduction downstream of the TCR 101 . In principle, T cells engineered to express high-avidity or high-affinity TCRs could be produced in large numbers and used to kill infected T cells at an earlier point in the viral life cycle, when fewer peptide-major histocompatibility complexes (MHC) are available to be targeted at the cell surface. In addition, such TCRs could limit the generation of escape mutants. A general limitation of this approach for humans is that each TCR is specific for a given peptide-MHC complex, such that each vector would be useful only for individuals with shared MHC alleles and HIV-1 infections that retain and express the targeted epitope. Another technical issue with the redirected TCR approach is the potential for off-target effects due to mispairing of modified TCR chains with endogenous TCR chains. Several approaches to direct the pairing and induce 'allelic exclusion' of natural TCR genes have been described, including introduction of an artificial disulfide bond, which is reported to increase surface expression and pairing efficiency 102 .
Opportunities and future directions of T-cell gene therapy. In contrast to the challenges of evaluating the efficacy of stem-cell gene therapy, an attractive feature of T-cell approaches is that it is straightforward to determine therapeutic effects. Brief analytical treatment interruptions, if carefully performed, are safe and can provide definitive information on the antiviral efficacy of the vector by measuring changes in viral load or CD4 + cell counts over time after the interruption. Because the correlates of immune protection are largely unknown, and although anti-HIV-1 effects can be assessed in vitro, the best way to test the functionality of the antiviral response is to discontinue therapy and investigate the ability of the engineered host responses to control viral replication and protect CD4 + cells. Longterm structured treatment interruptions may increase the risk of HIV progression and are discouraged.
The availability of preclinical models in which to optimize vectors is essential. Studies in nonhuman primates are costly, and host restriction factors may preclude testing of lentiviral vectors in these models. Rather than re-engineering vectors into viruses that are permissive to nonhuman primates, it is preferable to test candidate vectors in human cells. Improved humanized mouse models of HIV-1 infection 103,104 may be useful for preclinical vector testing.
In T-cell gene therapy, preservation of the replicative life span of memory T cells is probably vital for long-term antiviral effects and immune protection. Given that HIV-1 infection induces changes consistent with accelerated aging of the immune system 105 Because HS cells proliferate extensively once they begin to contribute to blood cell production, any introduced genetic modification must be permanent so that it will be passed on to the progeny cells. Most efforts to add anti-HIV-1 genes have used gamma-retroviral vectors derived from the Moloney MLV, which covalently integrates the gene into the cellular chromosome 108 . More recently, lentiviral vectors derived from HIV-1 are being investigated for HS cell gene therapy, with several clinical trials under development 109, 110 . Lentiviral vectors have the potential to transduce a greater percentage of HS cells with a shorter ex vivo culture duration than gamma-retroviral vectors 108 . Although there is a theoretical potential for recombination between the minimal HIV-1-derived sequences present in the lentiviral vector backbone and a person's wild-type HIV-1, it is difficult to imagine a recombinant that would be more pathogenic than the wild-type virus. Some anti-HIV-1 genes may interfere with the production of HIV-1-based lentiviral vectors, which may limit their use in the clinic if sufficient titers cannot be achieved.
In several preclinical studies, human (or rhesus) CD34 + cells were modified with anti-HIV genes, differentiated to produce monocytic cells or T lymphocytes in vitro and then challenged with HIV-1 infection to assess the conferred inhibition of HIV-1 replication 6, [111] [112] [113] [114] . Although viral replication was effectively impaired, the major limitation of these in vitro studies is that they used relatively mature progenitor cells rather than true HS cells, which lead to long-term lymphopoiesis after transplant. A few studies in immune-deficient mouse xenograft models have shown that mature T cells produced from transduced human CD34 + cells were relatively resistant to HIV-1 infection [115] [116] [117] . Surprisingly, there have been no reported studies in nonhuman primate models transplanted with autologous CD34 + cells transduced with anti-HIV genes and challenged in vivo with simian immunodeficiency virus, to test this approach in the most relevant preclinical models. The Chen group 118 has recently shown that HS cells transduced with a lentivirus to express an siRNA against CCR5 have stable long-term reduction of CCR5 in nonhuman primates, with resistance to simian immunodeficiency virus infection after ex vivo growth 118 .
The results of clinical trials for HIV-1 using HS cells have been modest 14, 78, 119, 120 . The numbers of peripheral blood cells containing the introduced gene have been low or undetectable in most subjects after the first few months, indicating low engraftment of gene-modified HS cells. One child had a late reappearance of CD4 + T cells containing an anti-HIV-1 gene during a period of noncompliance with HAART and an HIV-1 resurgence, suggesting a relative selective survival advantage of gene-protected cells 121 . On the basis of these findings of low numbers of gene-marked cells, current efforts are directed at increasing the gene transduction of HS cells using lentiviral vectors instead of gamma-retroviral vectors.
In recent clinical trials of gene therapy for genetic diseases of blood cells, the administration of chemotherapy agents intended to ablate some of the endogenous bone marrow (for example, busulfan or melphalan) before reinfusing the ex vivo gene-modified HS cells has significantly increased the fraction of gene-modified cells in circulation 122, 123 . Except for X-linked severe combined immune deficiency, where the selective advantage of genetically normal lymphoid progenitors is very strong 124 , it will probably be necessary to use cytoreductive conditioning for HS cell gene therapy to produce a significant percentage of gene-modified cells. These agents add to the risks of the procedure, both from potential short-term toxicity and from potential adverse effects on residual immunity. However, the experience in the setting of genetic disease has shown that dosages of these agents that are well tolerated clinically do considerably increase the amount of engrafting of gene-modified HS cells.
Safety concerns were raised by the major adverse effect of insertional oncogenesis that occurred in infants with X-linked severe combined immune deficiency undergoing gene therapy 125 . Particularly high-risk features in those cases may have included the specific transgene, γC, encoding a cytokine receptor protein, which may provide a subtle proliferative signal to cells, the relatively high number of bone marrow CD34 + cells that were present in the infants' marrow and the massive lymphoid expansion that occurred upon engraftment of the corrected cells, possibly aided by the highly supportive thymic microenvironment present during infancy. In contrast, in HIV-1 gene therapy the genes themselves are not expected to confer any autonomous proliferative capacity on cells, the content of bone marrow stem cells may be lower in older individuals with HIV-1 infection, and prolonged antiretroviral therapy and the thymic function may be greatly diminished. Thus, the same factors that currently limit the efficacy of gene therapy for HIV-1 using HS cells may also limit the risks.
Genetically modified HS cells may show complex patterns of proliferation, with some clones proliferating early but then becoming exhausted, whereas others may be quiescent for some months and then proliferate to produce blood cells 126 . De novo production of peripheral blood T cells after bone marrow transplant with CD34 + cells in persons with X-linked severe combined immune deficiency who lack endogenous lymphocytes takes at least 3 months, with migration and differentiation of marrow-derived lymphoid progenitors in the thymus being a limiting step. CD34 + populations include a subset of common lymphoid progenitors (CLPs) that are restricted in their differentiation capacity to production of only lymphoid, and not myeloid, cells 127 . CLPs may be responsible for the initial wave of lymphopoiesis after transplant of CD34 + cells, and transduced CLPs may give rise to the first wave of protected T cells after a few months. Although expansion of HS cells has not been convincingly achieved, expansion of human CLPs has been successful, and increased numbers of CLPs may shorten the lag of de novo lymphopoiesis. Gene-modified CLPs expanded in vitro may play a role in the rapid production of gene-protected T cells.
Conclusions
Many options are available for using gene therapy in the treatment of HIV infection, whether the transgene encodes an RNA-based or protein-based agent. The major issues facing the field are targeting specificity of the anti-HIV gene (maximal activity against HIV-1 and minimal cellular toxicity), averting viral resistance and potential antigenicity of the antiviral agents. Considering the continuing health and financial costs of the HIV-1 epidemic, it is prudent to continue to explore a variety of therapeutic strategies. Gene therapy has the potential to complement conventional antiretroviral therapies and to augment the effects of currently available vaccine technologies that fall short of desired efficacy. Combining gene-modified CD4 + T cells and CD34 + HS cells may yield additive effects (Fig. 3) . The transfused T cells would be present immediately but decline over time, whereas the CD34 + cells would produce T cells over subsequent months. If these T cells contributed to immunity or otherwise diminished HIV-1 replication, their more prolonged presence may be beneficial.
Several clinical trials testing gene transfer strategies in T cells and HS cells have been reported or are in development ( Table 1) . Although progress and benefits from genetic therapies for HIV-1 have come more slowly than hoped, the same may be said for results of the far larger effort at developing an HIV-1 vaccine. Thus far, no gene transfer trials that test combination approaches have been carried out. In light of the success achieved with combined drugs in HAART, it makes the most sense to devise gene therapy schemes in which combinations of antiviral genes are co-expressed in target hematopoietic cells. Targeting combinations of CCR5 and viral genes also has a theoretical advantage over simply targeting cellular or viral genes. Given the repertoire of antiviral genes now available, this should be the goal of future gene therapy trials.
